{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:17:30Z","timestamp":1746245850305},"reference-count":30,"publisher":"Societas Neurologica Japonica","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rinsho Shinkeigaku"],"published-print":{"date-parts":[[2023]]},"DOI":"10.5692\/clinicalneurol.cn-001908","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:10:49Z","timestamp":1700604649000},"page":"830-835","source":"Crossref","is-referenced-by-count":1,"title":["A case of anti-acetylcholine receptor antibody-positive ocular myasthenia gravis with anti-titin antibody and anti-Kv1.4 antibody positive inflammatory myopathy","\u6297titin\u6297\u4f53\u30fb\u6297Kv1.4\u6297\u4f53\u3092\u4f34\u3046\u708e\u75c7\u6027\u7b4b\u75be\u60a3\u3092\u5408\u4f75\u3057\u305f\uff0c\u6297AChR\u6297\u4f53\u967d\u6027\u773c\u7b4b\u578b\u91cd\u75c7\u7b4b\u7121\u529b\u75c7\u306e1\u4f8b"],"prefix":"10.5692","volume":"63","author":[{"given":"Kenshiro","family":"Fuse","sequence":"first","affiliation":[{"name":"Department of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amane","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Morozumi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kazuta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine"},{"name":"Department of Neurology, Chutoen General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine"},{"name":"Department of Neurology, National Hospital Organization Suzuka Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine"},{"name":"Department of Clinical Research Education, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3663","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009;66:1334-1338.","DOI":"10.1001\/archneurol.2009.229"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Santos E, Coutinho E, Martins da Silva A, et al. Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: report of four cases and literature review. Autoimmun Rev 2017;16:644-649.","DOI":"10.1016\/j.autrev.2017.04.009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Huang K, Shojania K, Chapman K, et al. Concurrent inflam\u00admatory myopathy and myasthenia gravis with or without thymic pathology: a case series and literature review. Semin Arthritis Rheum 2019;48:745-751.","DOI":"10.1016\/j.semarthrit.2018.05.004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Uchio N, Taira K, Ikenaga C, et al. Inflammatory myopathy with myasthenia gravis: thymoma association and polymyositis pathology. Neurol Neuroimmunol Neuroinflamm 2018;6:e535.","DOI":"10.1212\/NXI.0000000000000535"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Garibaldi M, Fionda L, Vanoli F, et al. Muscle involvement in \u200dmyasthenia gravis: expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients. Autoimmun Rev 2020;19:102498.","DOI":"10.1016\/j.autrev.2020.102498"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Suzuki S, Utsugisawa K, Nagane Y, et al. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011;2011:740583.","DOI":"10.4061\/2011\/740583"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kerty E, Elsais A, Argov Z, et al. EFNS\/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 2014;21:687-693.","DOI":"10.1111\/ene.12359"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.","DOI":"10.1002\/mus.20950"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Otton SH, Standen GR, Ormerod IE. T cell lymphocytosis associated with polymyositis, myasthenia gravis and thymoma. Clin Lab Haematol 2000;22:307-308.","DOI":"10.1046\/j.1365-2257.2000.00312.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kanbayashi T, Tanaka S, Hatanaka Y, et al. Myasthenia gravis with inflammatory myopathy without elevation of creatine kinase. Neuromuscul Disord 2021;31:570-573.","DOI":"10.1016\/j.nmd.2021.03.010"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Marcuse F, Brandts L, Moens D, et al. The association between anti-acetylcholine receptor antibody level and clinical improve\u00adment in myasthenia gravis. Eur J Neurol 2022;29:1187-1197.","DOI":"10.1111\/ene.15238"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supple\u00adment to the Guidelines of the German Neurological Society. J \u200dNeurol 2016;263:1473-1494.","DOI":"10.1007\/s00415-016-8045-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89:1127-1134.","DOI":"10.1212\/WNL.0000000000004359"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Gilhus NE, Skeie GO, Romi F, et al. Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol 2016;12:259-268.","DOI":"10.1038\/nrneurol.2016.44"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Romi F, Skeie GO, Aarli JA, et al. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000;57:1596-1600.","DOI":"10.1001\/archneur.57.11.1596"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Romi F, Suzuki S, Suzuki N, et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 2012;259:1312-1316.","DOI":"10.1007\/s00415-011-6344-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Decroos EC, Hobson-Webb LD, Juel VC, et al. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?: predictive value of antibodies. Muscle Nerve 2014;49:30-34.","DOI":"10.1002\/mus.23882"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Szczudlik P, Szyluk B, Lipowska M, et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand 2014;130:229-233.","DOI":"10.1111\/ane.12271"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Aspinall R, Andrew D. Thymic involution in aging. J Clin Immunol 2000;20:250-256.","DOI":"10.1023\/A:1006611518223"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 2020;94:e1171-e1180.","DOI":"10.1212\/WNL.0000000000008903"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers 2019;5:30.","DOI":"10.1038\/s41572-019-0079-y"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Vijayan J, Menon D, Barnett C, et al. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve 2021;64:462-466.","DOI":"10.1002\/mus.27369"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Akaishi T, Yamaguchi T, Suzuki Y, et al. Insights into the classification of myasthenia gravis. PLoS One 2014;9:e106757.","DOI":"10.1371\/journal.pone.0106757"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Zivkovi\u0107 SA, Clemens PR, Lacomis D. Characteristics of late-\u200donset myasthenia gravis. J Neurol 2012;259:2167-2171.","DOI":"10.1007\/s00415-012-6478-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Monte G, Spagni G, Damato V, et al. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? J Neurol 2021;268:1803-1807.","DOI":"10.1007\/s00415-020-10342-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013;12:875-884.","DOI":"10.1016\/j.autrev.2013.03.007"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kufukihara K, Watanabe Y, Inagaki T, et al. Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis. Sci Rep 2019;9:5284.","DOI":"10.1038\/s41598-019-41730-z"},{"key":"28","unstructured":"28) \u85e4\u7530\u7406\u5948\uff0c\u7684\u5834\u4fca\uff0c\u68ee\u7551\u5b8f\u4e00\u3089\uff0e\u8457\u660e\u306a\u5f90\u8108\u3092\u8a8d\u3081\u6297\u6a2a\u7d0b\u7b4b\u6297\u4f53\u304c\u967d\u6027\u3067\u3042\u3063\u305f\u9ad8\u9f62\u767a\u75c7\u306e\u91cd\u75c7\u7b4b\u7121\u529b\u75c7\u306e1\u4f8b\uff0e\u81e8\u5e8a\u795e\u7d4c 2021;61:543-546."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nagane Y, Suzuki S, Suzuki N, et al. Factors associated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 2010;41:212-218.","DOI":"10.1002\/mus.21462"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Zhou Z, Chen X, Liu G, et al. Presence of multiple autoimmune antibodies involved in concurrent myositis and myocarditis and myasthenia gravis without thymoma: a case report. Front Neurol 2019;10:770.","DOI":"10.3389\/fneur.2019.00770"}],"container-title":["Rinsho Shinkeigaku"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/63\/12\/63_cn-001908\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:41:03Z","timestamp":1715575263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/63\/12\/63_cn-001908\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5692\/clinicalneurol.cn-001908","relation":{},"ISSN":["0009-918X","1882-0654"],"issn-type":[{"value":"0009-918X","type":"print"},{"value":"1882-0654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"cn-001908"}}